MA32232B1 - Nouveaux compoés hétérocycliques et leurs utilisations - Google Patents

Nouveaux compoés hétérocycliques et leurs utilisations

Info

Publication number
MA32232B1
MA32232B1 MA33252A MA33252A MA32232B1 MA 32232 B1 MA32232 B1 MA 32232B1 MA 33252 A MA33252 A MA 33252A MA 33252 A MA33252 A MA 33252A MA 32232 B1 MA32232 B1 MA 32232B1
Authority
MA
Morocco
Prior art keywords
heterocyclic compounds
novel heterocyclic
novel
raf kinase
compositions
Prior art date
Application number
MA33252A
Other languages
Arabic (ar)
English (en)
Inventor
Zilin Huang
Jeff Jin
Timothy D Machajewski
William R Antonios-Mccrea
Maureen Mckenna
Daniel Poon
Paul A Renhowe
Martin Sendzik
Cynthia M Shafer
Aaron Smith
Yongjin Xu
Qiong Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40734805&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32232(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32232B1 publication Critical patent/MA32232B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne de nouveaux composés hétérocycliques substitués, des compositions les contenant et leurs procédés d'utilisation dans le cadre de l'inhibition de l'activité de la raf kinase. Les nouveaux composés et compositions peuvent être utilisés soit seuls, soit en combinaison avec au moins un agent supplémentaire afin de traiter un trouble induit par la raf kinase, tel que le cancer.
MA33252A 2008-03-21 2010-10-15 Nouveaux compoés hétérocycliques et leurs utilisations MA32232B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3872308P 2008-03-21 2008-03-21
US20845809P 2009-02-24 2009-02-24
PCT/EP2009/053245 WO2009115572A2 (fr) 2008-03-21 2009-03-19 Nouveaux composés hétérocycliques et leurs utilisations

Publications (1)

Publication Number Publication Date
MA32232B1 true MA32232B1 (fr) 2011-04-01

Family

ID=40734805

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33252A MA32232B1 (fr) 2008-03-21 2010-10-15 Nouveaux compoés hétérocycliques et leurs utilisations

Country Status (26)

Country Link
US (1) US8129394B2 (fr)
EP (1) EP2274300A2 (fr)
JP (2) JP5384611B2 (fr)
KR (2) KR101408517B1 (fr)
CN (1) CN102015686B (fr)
AR (1) AR071283A1 (fr)
AU (1) AU2009227013B2 (fr)
BR (1) BRPI0908906A2 (fr)
CA (1) CA2718936A1 (fr)
CL (1) CL2009000687A1 (fr)
CO (1) CO6311078A2 (fr)
CR (1) CR11681A (fr)
DO (1) DOP2010000280A (fr)
EA (1) EA201001456A1 (fr)
EC (1) ECSP10010559A (fr)
IL (1) IL208063A0 (fr)
MA (1) MA32232B1 (fr)
MX (1) MX2010010317A (fr)
NI (1) NI201000156A (fr)
PE (1) PE20091656A1 (fr)
SM (1) SMAP201000115A (fr)
SV (1) SV2010003673A (fr)
TW (1) TW201000457A (fr)
UY (1) UY31724A (fr)
WO (1) WO2009115572A2 (fr)
ZA (1) ZA201006505B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP2535330A3 (fr) * 2006-10-23 2012-12-26 Takeda Pharmaceutical Company Limited Dérivé d'iminopyridine et son utilisation
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
US8268834B2 (en) * 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
US8865732B2 (en) * 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AR071392A1 (es) * 2008-04-23 2010-06-16 Takeda Pharmaceutical Derivados de iminopiridina y su uso
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
US8481569B2 (en) * 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
AR077975A1 (es) * 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011090738A2 (fr) 2009-12-29 2011-07-28 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
EP3354652B1 (fr) 2010-03-10 2020-05-06 Incyte Holdings Corporation Dérivés de pipéridine-4-yl azétidine utilisés en tant qu'inhibiteurs de jak1
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
AU2011274914B2 (en) * 2010-07-09 2013-07-18 Mitsubishi Gas Chemical Company, Inc. Photochromic material
EP2593451B1 (fr) 2010-07-12 2015-08-19 Bayer Intellectual Property GmbH Imidazo[1,2-a]pyrimidines et -pyridines substitués
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US8791112B2 (en) * 2011-03-30 2014-07-29 Arrien Pharmaceuticals Llc Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9498471B2 (en) 2011-10-20 2016-11-22 The Regents Of The University Of California Use of CDK9 inhibitors to reduce cartilage degradation
RU2622015C2 (ru) 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
SI2782557T1 (sl) 2011-11-23 2019-02-28 Array Biopharma, Inc., Farmacevtske formulacije
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159735B (zh) * 2011-12-10 2015-12-09 通化济达医药有限公司 取代的咪唑激酶抑制剂
TW201332989A (zh) * 2011-12-23 2013-08-16 Millennium Pharm Inc 雜芳基化合物及其用途
WO2013166413A2 (fr) * 2012-05-03 2013-11-07 Saint Louis College Of Pharmacy Compositions et procédés pour augmenter des peptides neurotrophiques
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2014047330A1 (fr) * 2012-09-19 2014-03-27 Jean-Michel Vernier Nouveaux inhibiteurs de raf kinase
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CA3000633C (fr) 2014-10-14 2023-10-03 The Regents Of The University Of California Utilisation d'inhibiteurs de cdk9 et d'inhibiteurs de brd4 pour inhiber une inflammation
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
KR101665231B1 (ko) * 2015-01-30 2016-10-13 순천향대학교 산학협력단 티오페닐 그룹을 갖는 티아졸계 화합물 및 이를 유효성분으로 포함하는 항진균제
CA2975988C (fr) * 2015-02-04 2020-07-21 Medpacto Inc. Combinaison d'inhibiteur de tgf-8 et d'inhibiteur de tyrosine kinase de bcr-abl pour le traitement de la leucemie myeloide chronique
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
GB201614934D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
AU2017363307B2 (en) 2016-11-22 2021-07-29 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof
AR113206A1 (es) 2017-01-10 2020-02-19 Bayer Cropscience Ag Derivados heterocíclicos como pesticidas
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
WO2018146253A1 (fr) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de cancers associés à l'activation de la voie mapk
WO2019005241A1 (fr) 2017-03-23 2019-01-03 Clavius Pharmaceuticals, Llc Imidazoles tri-substitués pour l'inhibition de tgf-bêta et méthodes de traitement
CA3057969A1 (fr) 2017-05-02 2018-11-08 Novartis Ag Polytherapie
JP7038994B2 (ja) * 2017-10-16 2022-03-22 国立大学法人金沢大学 炭素繊維強化プラスチックの製造方法、炭素繊維強化プラスチック及びセルロース系樹脂
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
WO2019133810A1 (fr) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Systèmes de culture de cellules souches pour cellules souches épithéliales colonnaires, et leurs utilisations
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
EP3810132A4 (fr) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase de la famille taire et utilisations correspondantes
WO2020011141A1 (fr) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 Composé diarylpyrazole, composition le comprenant et utilisation associée
WO2020041562A1 (fr) 2018-08-22 2020-02-27 Clavius Pharmaceuticals, Llc Imidazoles substitués pour l'inhibition de tgf-bêta et méthodes de traitement
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
WO2020150091A1 (fr) 2019-01-15 2020-07-23 Merck Sharp & Dohme Corp. Inhibiteurs d'histone désacétylase utiles pour le traitement ou la prévention d'une infection par le vih
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020192302A1 (fr) * 2019-03-27 2020-10-01 广州必贝特医药技术有限公司 Composé d'imidazole tri-substitué contenant de la pyrimidine et utilisation associée
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
EP3969449B1 (fr) 2019-05-13 2025-02-12 Novartis AG Nouvelles formes cristallines de n-(3-(2-(2-hydroxyéthoxy)-6-morpholinopyridin-4-yl)-4-méthylphényl)-2(trifluorométhyl)isonicotinamide servant d'inhibiteurs de raf pour le traitement du cancer
CA3150681A1 (fr) 2019-08-14 2021-02-18 Incyte Corporation Composes imidazolyl-pyrimidinylamines utilises comme inhibiteurs de la cdk2
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR20230039665A (ko) 2020-07-02 2023-03-21 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11905272B1 (en) 2023-09-12 2024-02-20 King Faisal University 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anti-cancer compound
US11932619B1 (en) 2023-09-13 2024-03-19 King Faisal University 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine as an anticancer compound
US11993579B1 (en) 2023-09-13 2024-05-28 King Faisal University 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1h-imidazol-2-yl)pyridin-4-ol as an anti-microbial compound

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
JPS5613715A (en) * 1979-07-13 1981-02-10 Nec Corp Manufacture of coil
DE3029376A1 (de) * 1980-07-31 1982-03-18 Nepera Chemical Co. Inc., Harriman, N.Y. Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
US5243517A (en) * 1988-08-03 1993-09-07 Westinghouse Electric Corp. Method and apparatus for physiological evaluation of short films and entertainment materials
JP2722586B2 (ja) 1989-01-13 1998-03-04 大正製薬株式会社 インドリルイミダゾール誘導体
JP2808460B2 (ja) 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
US6850252B1 (en) * 1999-10-05 2005-02-01 Steven M. Hoffberg Intelligent electronic appliance system and method
US5436830A (en) * 1993-02-01 1995-07-25 Zaltman; Gerald Metaphor elicitation method and apparatus
US5676148A (en) * 1995-03-31 1997-10-14 Siemens Medical Systems Inc. Method and system for doppler ultrasound audio dealiasing
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
KR19990064117A (ko) * 1995-10-06 1999-07-26 폴락 돈나 엘. 항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸
US5676138A (en) * 1996-03-15 1997-10-14 Zawilinski; Kenneth Michael Emotional response analyzer system with multimedia display
US6268308B1 (en) * 1996-08-27 2001-07-31 Syngenta Crop Protection, Inc. Herbicidal S-substituted 1,2,4,6-thiatriazines
US6099319A (en) * 1998-02-24 2000-08-08 Zaltman; Gerald Neuroimaging as a marketing tool
US6315569B1 (en) * 1998-02-24 2001-11-13 Gerald Zaltman Metaphor elicitation technique with physiological function monitoring
US6358201B1 (en) * 1999-03-02 2002-03-19 Doc L. Childre Method and apparatus for facilitating physiological coherence and autonomic balance
JP2000302680A (ja) * 1999-04-23 2000-10-31 Takeda Chem Ind Ltd 脳保護剤
AU1529901A (en) * 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
JP2003520233A (ja) * 2000-01-18 2003-07-02 バーテックス ファーマシューティカルズ インコーポレイテッド ジャイレースインヒビターおよびそれらの使用
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
AU2001264679A1 (en) * 2000-05-19 2001-12-03 The Nutrasweet Company Synthesis of n-(n-(3,3-dimethylbutyl)-l-alpha-aspartyl)-l-phenylalanine 1-methylester using oxazolidinone derivatives
ATE365730T1 (de) * 2000-11-20 2007-07-15 Smithkline Beecham Corp Neuartige verbindungen
ES2274005T3 (es) * 2001-01-26 2007-05-16 Chugai Seiyaku Kabushiki Kaisha Inhibidores de malonyl-coa decarboxilasa usados como moduladores metabolicos.
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
MXPA05002981A (es) * 2002-09-18 2005-06-22 Pfizer Prod Inc Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf).
CA2545942C (fr) * 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Imidazoles d'aryle et leur utilisation comme agents anticancereux
RU2367661C2 (ru) * 2004-03-05 2009-09-20 Тайсо Фармасьютикал Ко., Лтд. Производные тиазола
KR100749566B1 (ko) 2004-04-21 2007-08-16 이화여자대학교 산학협력단 Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
US20060106020A1 (en) * 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
JP2007246520A (ja) * 2006-02-15 2007-09-27 Takeda Yuichiro Ｒａｇｅ阻害剤

Also Published As

Publication number Publication date
ZA201006505B (en) 2011-05-25
US20100003246A1 (en) 2010-01-07
ECSP10010559A (es) 2010-11-30
CN102015686A (zh) 2011-04-13
UY31724A (es) 2009-11-10
SV2010003673A (es) 2011-07-05
WO2009115572A2 (fr) 2009-09-24
PE20091656A1 (es) 2009-11-20
KR101408517B1 (ko) 2014-06-17
JP2011515371A (ja) 2011-05-19
MX2010010317A (es) 2010-10-04
SMAP201000115A (it) 2011-01-19
IL208063A0 (en) 2010-12-30
CR11681A (es) 2010-10-29
KR20100136516A (ko) 2010-12-28
AU2009227013B2 (en) 2013-01-10
EP2274300A2 (fr) 2011-01-19
CO6311078A2 (es) 2011-08-22
CN102015686B (zh) 2014-07-02
CA2718936A1 (fr) 2009-09-24
JP2014040452A (ja) 2014-03-06
AR071283A1 (es) 2010-06-09
TW201000457A (en) 2010-01-01
JP5384611B2 (ja) 2014-01-08
AU2009227013A1 (en) 2009-09-24
BRPI0908906A2 (pt) 2019-09-24
NI201000156A (es) 2011-03-15
CL2009000687A1 (es) 2010-03-26
US8129394B2 (en) 2012-03-06
DOP2010000280A (es) 2012-09-15
KR20130040258A (ko) 2013-04-23
WO2009115572A3 (fr) 2009-12-03
EA201001456A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
MA32232B1 (fr) Nouveaux compoés hétérocycliques et leurs utilisations
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA29141B1 (fr) Pyrrolopyrazoles, servant de puissants inhibiteurs de kinases
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
MA53668B1 (fr) Traitement de la drépanocytose avec un composé activant la pyruvate kinase r
MX2009009948A (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa.
MX2009003821A (es) Compuestos de n-aril pirazol para usarse contra la diabetes.
SI2134691T1 (sl) Derivati kvinolina kot PARP in TANK inhibitorji
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MX2007010272A (es) Inhibidores de moleculas pequenas de mdm2 y usos de los mismos.
DE60137966D1 (de) Anilinopyrimidin derivate als "jnk pathway inhibitoren", zusammensetzungen und damit verbundene behandlungsmethoden
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
MX2009002306A (es) Nuevos inhibidores de mdm2 de molecula pequeña y sus usos.
TW200740799A (en) Alpha2C adrenoreceptor agonists
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201100378A1 (ru) Модуляторы сигнального пути hedgehog
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MX382737B (es) Composiciones estabilizadas que comprenden nitrato de amonio.
GB0510143D0 (en) Novel compounds A1
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA31761B1 (fr) Nouveaux inhibiteurs de seh et leur utilisation
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов